Status
Conditions
Treatments
About
The aim of this study is to evaluate the efficacy and safety of simiaowan in prevention of acute flares in chronic gout patients initiating febuxostat therapy.
Full description
The study is a multicenter, randomized, double-blind, placebo-controlled, 12-week trial. To determine whether oral simiaowan at standard clinical doses (6g twice daily), compared to placebo, can reduce the incidence of acute gout flares and decrease the serum uric acid level.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
72 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Jiang Quan, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal